Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.
Salvatore D, Terlizzi V, Francalanci M, Taccetti G, Messore B, Biglia C, Pisi G, Calderazzo MA, Caloiero M, Pizzamiglio G, Majo F, Cresta F, Leonetti G, De Venuto D.
Salvatore D, et al. Among authors: terlizzi v.
Respir Med. 2020 Sep;171:106073. doi: 10.1016/j.rmed.2020.106073. Epub 2020 Jul 3.
Respir Med. 2020.
PMID: 32846335
Free article.